- Home
- TOPS vs EQ Comparison
TOPS vs EQ Comparison
Compare TOPS & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- EQ
- Stock Information
- Founded
- TOPS 2000
- EQ 2017
- Country
- TOPS Greece
- EQ United States
- Employees
- TOPS N/A
- EQ N/A
- Industry
- TOPS Marine Transportation
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- EQ Health Care
- Exchange
- TOPS Nasdaq
- EQ Nasdaq
- Market Cap
- TOPS 41.4M
- EQ 39.0M
- IPO Year
- TOPS 2004
- EQ 2018
- Fundamental
- Price
- TOPS $7.57
- EQ $0.71
- Analyst Decision
- TOPS
- EQ Buy
- Analyst Count
- TOPS 0
- EQ 2
- Target Price
- TOPS N/A
- EQ $5.00
- AVG Volume (30 Days)
- TOPS 9.5K
- EQ 311.1K
- Earning Date
- TOPS 11-26-2024
- EQ 11-13-2024
- Dividend Yield
- TOPS N/A
- EQ N/A
- EPS Growth
- TOPS N/A
- EQ N/A
- EPS
- TOPS N/A
- EQ N/A
- Revenue
- TOPS $83,870,000.00
- EQ $45,914,000.00
- Revenue This Year
- TOPS $7.10
- EQ N/A
- Revenue Next Year
- TOPS $6.54
- EQ N/A
- P/E Ratio
- TOPS N/A
- EQ N/A
- Revenue Growth
- TOPS 1.10
- EQ 7.70
- 52 Week Low
- TOPS $6.70
- EQ $0.48
- 52 Week High
- TOPS $18.97
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- TOPS 31.78
- EQ 39.09
- Support Level
- TOPS $7.50
- EQ $0.68
- Resistance Level
- TOPS $8.25
- EQ $0.89
- Average True Range (ATR)
- TOPS 0.52
- EQ 0.11
- MACD
- TOPS -0.03
- EQ -0.03
- Stochastic Oscillator
- TOPS 5.53
- EQ 5.49
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The company focuses on the transportation of petroleum products (clean and dirty) and bulk liquid chemicals. The Company is an international provider of worldwide oil, petroleum products and chemical transportation services. It generates revenue from the Time Charter agreements.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.